Phaseline

Companies › Advanced Accelerator Applications

Advanced Accelerator Applications: clinical trials, targets and expected readouts

1 active drug program in 28 registered trials: 17 Phase 2, 8 Phase 1, 2 Phase 3, 1 Phase 4; Gastroenterology, Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3Gastro-enteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumors; Digestive System Neuroendocrine Tumor G1; Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) …Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04609592Lutetium Oxodotreotide Lu-177Phase 1Gastroenteropancreatic Neuroendocrine TumorGastroenterologyNov 2026
NCT06663072Lutetium Oxodotreotide Lu-177Phase 1Metastatic Pancreatic Neuroendocrine TumorOncologyNov 2026
NCT05724108Lutetium Oxodotreotide Lu-177Phase 2Metastatic Neuroendocrine TumorOncologyDec 2026
NCT05687123Lutetium Oxodotreotide Lu-177Phase 1Metastatic Pancreatic Neuroendocrine TumorOncologyDec 2026
NCT03971461Lutetium Oxodotreotide Lu-177Phase 2MeningiomaOncologyJan 2027
NCT04234568Lutetium Oxodotreotide Lu-177Phase 1Metastatic Digestive System Neuroendocrine NeoplasmOncologyMar 2027
NCT06326190Lutetium Oxodotreotide Lu-177Phase 2Recurrent MeningiomaOncologyApr 2027
NCT06016855Lutetium Oxodotreotide Lu-177Phase 4Digestive System Neuroendocrine Tumor G1OncologyMay 2027
NCT05691465Lutetium Oxodotreotide Lu-177Phase 2Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationOncologyJun 2027
NCT04082520Lutetium Oxodotreotide Lu-177Phase 2Grade 1 MeningiomaOncologySep 2027
NCT07150546Lutetium Oxodotreotide Lu-177Phase 1Digestive System Neuroendocrine TumorGastroenterologySep 2027
NCT05247905Lutetium Oxodotreotide Lu-177Phase 2Metastatic Pancreatic Neuroendocrine TumorOncologyOct 2027
NCT03972488Lutetium Oxodotreotide Lu-177Phase 3Gastro-enteropancreatic Neuroendocrine TumorGastroenterologyOct 2027
NCT05249114Lutetium Oxodotreotide Lu-177Phase 1Neuroendocrine TumorsOncologyDec 2027
NCT04529044Lutetium Oxodotreotide Lu-177Phase 2Anatomic Stage IV Breast Cancer AJCC v8OncologyDec 2027
NCT06126588Lutetium Oxodotreotide Lu-177Phase 2MeningiomaOncologyMay 2028
NCT05278208Lutetium Oxodotreotide Lu-177Phase 1High Grade GliomaOncologyNov 2028
NCT05583708Lutetium Oxodotreotide Lu-177Phase 2Merkel Cell CarcinomaOncologyDec 2028
NCT06878664Lutetium Oxodotreotide Lu-177Phase 3Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)OncologyJan 2029
NCT05178693Lutetium Oxodotreotide Lu-177Phase 1Neuroendocrine TumorsOncologyFeb 2029
NCT02754297Lutetium Oxodotreotide Lu-177Phase 2Neuroendocrine TumorsOncologyApr 2029
NCT05773274Lutetium Oxodotreotide Lu-177Phase 2Metastatic Digestive System Neuroendocrine Tumor G1OncologyApr 2029
NCT06955169Lutetium Oxodotreotide Lu-177Phase 2Intracranial MeningiomaOncologyAug 2029
NCT06395402Lutetium Oxodotreotide Lu-177Phase 2Neuroendocrine TumorsOncologyDec 2029
NCT04903899Lutetium Oxodotreotide Lu-177Phase 2Neuroblastoma RecurrentOncologyMay 2031
NCT04665739Lutetium Oxodotreotide Lu-177Phase 2Advanced Lung Neuroendocrine TumorOncologySep 2032
NCT04954820Lutetium Oxodotreotide Lu-177Phase 2Neuroendocrine TumorsOncologyOct 2033
NCT04711135Lutetium Oxodotreotide Lu-177Phase 2Gastroenteropancreatic Neuroendocrine TumorsOncologyFeb 2034

Targets

SSTR5 (1) SSTR2 (1) SSTR4 (1) SSTR1 (1) SSTR3 (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio CSPC ZhongQi Pharmaceutical Technology RECORDATI GROUP ITM Solucin Debiopharm International Nanjing Chia-tai Tianqing Pharmaceutical Orano Med

Companies built like this

Camurus ITM Solucin Orano Med 3D Medicines (Sichuan) PharmaEssentia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.